Theragnostics is an innovative radiopharmaceutical company with a portfolio of products in development. Our mission is to drive innovation in the fight against cancer. Enhancing patients’ lives with precision radiopharmaceuticals for personalized medicine. We will bring radiopharmaceuticals to the market that are used for the management and treatment of cancer patients. Theragnostics aims to be with the patient from initial diagnosis through to therapy.
We completed our Phase 2 clinical trial and starting our Phase 3 trial for our lead imaging candidate, Gallium-68 THP-PSMA, for PET imaging of prostate cancer.
Our new product, radiolabeled PARPi, is completing a Phase 1 diagnostic trial in head & neck cancer and will soon begin a Phase 2 basket study and a Phase 1 targeted radionuclide therapy.